ANI Pharma (ANIP) Tops Q4 EPS by 36c ; Offers Guidance

ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $2.33, $0.36 better than the analyst estimate of $1.97. Revenue for the quarter came in at $247.06 million versus the consensus estimate of $232.37 million.

GUIDANCE:

ANI Pharma sees FY2026 EPS of $8.83-$9.34, versus the consensus of $8.64. ANI Pharma sees FY2026 revenue of $1.05-1.12 billion, versus the consensus of $1.03 billion.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• HDFC Asset Management Co Ltd (HDFCAMC:IN) PT Raised to INR3,250 at JPMorgan
• JPMorgan Starts Angel One Ltd (ANGELONE:IN) at Overweight